Login
Companies $TRAW
$0.26 +$0.00 (0.0%) After hours
Traws Pharma, Inc. logo

Traws Pharma, Inc.

trawspharma.com

What Do They Do?

Develops investigational oral antiviral therapies for influenza and COVID, and cancer drug candidates for people with solid tumors and blood cancers.

How Do They Make Money?

The company earns money by licensing rights to product candidates; partners can pay upfront, when development or regulatory milestones are met, and royalties on sales of licensed products.

FY2025 revenue

Who Are Their Customers?

Other companies license rights to product candidates; if products reach market, Traws may use licensing or co-promotion partners for marketing and distribution.

Do Revenues Turn Into Profits?

Yes. Its net income in FY2025 was larger than its revenue, but spent more cash than it brought in: free cash flow was −$20.8M.

Operating income, FY2025
−641% of revenue
▲ +87% (Loss) vs FY2024 (−$142.4M, −62997%)
Net income, FY2025
329% of revenue
▲ Turned profitable vs FY2024 (−$166.5M, −73683%)
Free cash flow, FY2025
−744% of revenue
▲ +38% (Loss) vs FY2024 (−$33.4M, −14796%)

How Are They Changing?

Since the FY2024 annual report
Latest quarter: Q2 FY2026, the three months to Jun 30, 2026
Net income
▼ −234% (Loss)
vs −$915K in Q2 FY2025

Growing. Revenue grew 12.3x in 4 years, from $226K in FY2021 to $2.8M in FY2025, about 87% a year.

Added respiratory-virus programs The older report describes a cancer-focused pipeline with narazaciclib and rigosertib. The latest report adds antiviral candidates for influenza and COVID while retaining those cancer programs.

Who Do They Compete With?

Competes with Gilead, Glaxo SmithKline, BioCryst, Roche, Cidara, Eradivir, Pfizer, Merck, Ridgeback, Novartis, and Eli Lilly

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support